California Pacific Medical Center

BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia

Retrieved on: 
Friday, November 17, 2023

NEW YORK, Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE. The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data. The presentation, titled, "NurOwn for ALS: Biomarker exploration of NurOwn multimodal mechanism of action on neuroinflammation, neuroprotection and neurodegeneration" will be presented by Bob Dagher, MD, Executive Vice President and Chief Development Officer at BrainStorm.

Key Points: 
  • Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes
    NEW YORK, Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE.
  • The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data.
  • The presentation, titled, "NurOwn for ALS: Biomarker exploration of NurOwn multimodal mechanism of action on neuroinflammation, neuroprotection and neurodegeneration" will be presented by Bob Dagher, MD, Executive Vice President and Chief Development Officer at BrainStorm.
  • A copy of the presentation will be available on the Events & Presentation page of Brainstorm's corporate website following the presentation.

Kyiv to Host International Healthcare Summit on War Zone Medicine

Retrieved on: 
Tuesday, October 31, 2023

COLUMBUS, Ohio, Oct. 31, 2023 /PRNewswire/ -- (JANZ Corporation) -- As war rages in Ukraine and Gaza, a former U.S. Surgeon General will be among the medical professionals gathering in Kyiv next week to discuss the challenges of providing medical care in active war zones.

Key Points: 
  • Surgeon General will be among the medical professionals gathering in Kyiv next week to discuss the challenges of providing medical care in active war zones.
  • To learn more and/or register to attend physically or virtually for the International Healthcare Summit-Ukraine 2023, please visit www.internationalhealthcaresummit.org .
  • "The situation in Ukraine is absolutely catastrophic," said Dr. Andrii Strokan, chief clinical medical officer at Feofaniya Hospital in Kyiv, Ukraine.
  • Strokan, who led the team of surgeons visiting the Mayo Clinic, will be joined in Kyiv at the healthcare summit by former Surgeon General of the United States (Acting), Rear Admiral
    (ret.)

American Liver Foundation Hosts Free Liver Cancer Conference for Patients and Families

Retrieved on: 
Wednesday, October 18, 2023

FAIRFIELD, N.J., Oct. 18, 2023 /PRNewswire/ -- October is Liver Cancer Awareness Month and American Liver Foundation is pleased to host The Educated Patient: A Liver Cancer Conference Presented on October 21stf from 11AM to 2PM ET. Now in its fourth year, this one-day virtual education program is created especially for liver cancer patients, family members or caregivers who can register for free. The conference offers presentations, workshops and opportunities for engagement with leading medical experts, researchers and others knowledgeable about the issues most relevant to those dealing with liver cancer.

Key Points: 
  • The one-day virtual event brings together patients, caregivers, leading medical experts and researchers
    FAIRFIELD, N.J., Oct. 18, 2023 /PRNewswire/ -- October is Liver Cancer Awareness Month and American Liver Foundation is pleased to host The Educated Patient: A Liver Cancer Conference Presented on October 21stf from 11AM to 2PM ET.
  • Now in its fourth year, this one-day virtual education program is created especially for liver cancer patients, family members or caregivers who can register for free .
  • ALF's free virtual Liver Cancer Conference is October 21st.
  • She added, "We hope that this year's conference will provide patients and their families with new knowledge, resources, and support."

SANUWAVE Signs Distribution Agreement With Pacific Medical, Inc.

Retrieved on: 
Tuesday, August 1, 2023

EDEN PRAIRIE, MN, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced a long term partnership with Pacific Medical, Inc. to distribute and sell the UltraMIST line of wound care products in the Western United States.  Pacific Medical is an award-winning leader in medical equipment sales and support (including insurance billing) with over 215 salaried sales representatives, 75 of which are dedicated to the wound care space, and has been integral to the growth of numerous innovative medical devices and technologies.

Key Points: 
  • Pacific Medical to bring its sales force of over 215 dedicated representatives covering seven western states to the SANUWAVE UltraMist line of directed energy wound care products.
  • Long-term agreement to develop and expand the market for SANUWAVE “Energy First” treatments.
  • EDEN PRAIRIE, MN, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced a long term partnership with Pacific Medical, Inc. to distribute and sell the UltraMIST line of wound care products in the Western United States.
  • “We are excited to be entering into business with such an established and well-respected firm with a history of helping to define new markets and innovations,” said SANUWAVE EVP of Sales Tim Hendricks.

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) Congress 2023

Retrieved on: 
Thursday, June 15, 2023

DUBLIN, June 15, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that two scientific posters detailing Mallinckrodt's latest research findings on the clinical outcomes of treatment with TERLIVAZ® (terlipressin) for injection and clinical management criteria for adult patients with hepatorenal syndrome (HRS) will be presented at the European Association for the Study of the Liver (EASL) Congress 2023 in Vienna, Austria, taking place June 21-24, 2023. Both posters will be presented on June 24, 2023, 9:00 a.m. – 5:00 p.m. CEST / 3:00 a.m. – 11:00 a.m. EDT.

Key Points: 
  • Both posters will be presented on June 24, 2023, 9:00 a.m. – 5:00 p.m. CEST / 3:00 a.m. – 11:00 a.m. EDT.
  • The CONFIRM trial is the largest-ever prospective, randomized clinical trial of terlipressin compared to placebo in patients with HRS type 1 (HRS-1).
  • Ineligibility for Liver Transplant: TERLIVAZ-related adverse reactions (respiratory failure, ischemia) may make a patient ineligible for liver transplantation, if listed.
  • For patients with high prioritization for liver transplantation (e.g., MELD ≥35), the benefits of TERLIVAZ may not outweigh its risks.

Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

Retrieved on: 
Monday, March 6, 2023

NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors.

Key Points: 
  • NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors.
  • "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus.
  • Dr. Ben received his medical degree from Norman Bethune College of Medicine and his MBA from the University of California, San Diego.
  • "I look forward to working with the talented Corbus team to develop CRB-701 and CRB-601 and realize their potential."

Board-Certified Dermatologist Dr. Elizabeth Wallace Joins Cherry Hills Dermatology in Englewood, Colorado

Retrieved on: 
Wednesday, March 1, 2023

DENVER, March 1, 2023 /PRNewswire-PRWeb/ -- Elizabeth Wallace, MD, a Harvard-trained Board-Certified Dermatologist, will begin seeing patients on February 27, 2023 at Cherry Hills Dermatology. Dr. Wallace provides medical, surgical, and cosmetic care to patients of all ages.

Key Points: 
  • Elizabeth Wallace, MD joins Cherry Hills Dermatology, a premier dermatology practice serving the Denver Metro Area.
  • DENVER, March 1, 2023 /PRNewswire-PRWeb/ -- Elizabeth Wallace, MD , a Harvard-trained Board-Certified Dermatologist, will begin seeing patients on February 27, 2023 at Cherry Hills Dermatology .
  • After completing her training at Harvard, Dr. Wallace worked as an Assistant Professor of Dermatology at the University of Colorado School of Medicine.
  • "We are thrilled to have a dermatologist of this stature join our team at Cherry Hills Dermatology, " said Dr. Annelise Dawson, founder of Cherry Hills Dermatology.

Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defects

Retrieved on: 
Wednesday, January 18, 2023

Trefoil Therapeutics , a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced the dosing of the first patient in its Phase 1 safety study evaluating TTHX1114 as a topical eye drop formulation designed to reduce the duration and impact of corneal epithelial defects.

Key Points: 
  • Trefoil Therapeutics , a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced the dosing of the first patient in its Phase 1 safety study evaluating TTHX1114 as a topical eye drop formulation designed to reduce the duration and impact of corneal epithelial defects.
  • Corneal epithelial defects are open “sores” in the outer layer of the cornea that develop from common infections, eye trauma and neurotrophic keratopathy.
  • “Corneal epithelial defects can develop quickly from eye trauma, bacterial or viral infections such as a herpes reactivation, or from Sjögren's syndrome, among many other causes.
  • “We are excited to take this important step to research TTHX1114 as a topical therapy,” said David Eveleth, Ph.D., President and CEO of Trefoil Therapeutics.

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

Retrieved on: 
Monday, October 24, 2022

DUBLIN, Oct. 24, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today announced that five scientific abstracts on the clinical and health economic outcomes of treatment with TERLIVAZ® (terlipressin) for adult patients with hepatorenal syndrome (HRS) involving rapid reduction in kidney function,1 will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Charlotte, North Carolina from October 21-26. TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function,1 an acute and life-threatening condition requiring hospitalization.2

Key Points: 
  • "With the recent FDA approval of TERLIVAZ, we are hopeful that we are one step closer to improving outcomes for these critically ill patients."
  • Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO2 decreases below 90%.
  • Serious or Fatal Respiratory Failure: Obtain baseline oxygen saturation and do not initiate TERLIVAZ in hypoxic patients.
  • For patients with high prioritization for liver transplantation (e.g., MELD 35), the benefits of TERLIVAZ may not outweigh its risks.

American Liver Foundation Hosts Free Liver Cancer Conference for Patients and Families

Retrieved on: 
Tuesday, September 27, 2022

FAIRFIELD, N.J., Sept. 27, 2022 /PRNewswire/ -- The American Liver Foundation is pleased to host its third annual, The Educated Patient: A Liver Cancer Conference Presented by Exelixis on October 7th and 8th from 11AM to 2PM ET. This two-day virtual education program is created especially for liver cancer patients and their family members or caregivers. Patients, caregivers and family members can register for free.

Key Points: 
  • The Educated Patient: A Liver Cancer Conference Presented by Exelixis offers presentations, workshops and opportunities for engagement with leading medical experts, researchers and others knowledgeable about the issues most relevant to those dealing with liver cancer .
  • "Living with liver cancer can be an isolating and confusing experience," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation.
  • "We are looking forward to the 3rd Annual Liver Cancer Conference for patients and caregivers.
  • The mission of the American Liver Foundation isto promote education, advocacy, support services and research for the prevention, treatment and cure of liver disease.